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The tumour microenvironment is an important factor for colorectal cancer prognosis, affecting the patient’s
immune response. Immune checkpoints, which regulate the immune functions of lymphocytes, may provide prog-
nostic power. This study aimed to investigate the prognostic value of the immune checkpoints TIM-3, LAG-3 and
PD-1 in patients with stage I–III colorectal cancer. Immunohistochemistry was employed to detect TIM-3, LAG-3,
PD-1 and PD-L1 in 773 patients with stage I–III colorectal cancer. Immune checkpoint protein expression was
assessed in tumour cells using the weighted histoscore, and in immune cells within the stroma using point cou-
nting. Scores were analysed for associations with survival and clinical factors. High tumoural LAG-3 (hazard ratio
[HR] 1.45 95% confidence interval [CI] 1.00–2.09, p = 0.049) and PD-1 (HR 1.34 95% CI 1.00–1.78,
p = 0.047) associated with poor survival, whereas high TIM-3 (HR 0.60 95% CI 0.42–0.84, p = 0.003), LAG-3
(HR 0.58 95% CI 0.40–0.87, p = 0.006) and PD-1 (HR 0.65 95% CI 0.49–0.86, p = 0.002) on immune cells
within the stroma associated with improved survival, while PD-L1 in the tumour (p = 0.487) or the immune cells
within the stroma (p = 0.298) was not associated with survival. Furthermore, immune cell LAG-3 was indepen-
dently associated with survival (p = 0.017). Checkpoint expression scores on stromal immune cells were combined
into a Combined Immune Checkpoint Stromal Score (CICSS), where CICSS 3 denoted all high, CICSS 2 denoted
any two high, and CICSS 1 denoted other combinations. CICSS 3 was associated with improved patient survival
(HR 0.57 95% CI 0.42–0.78, p = 0.001). The results suggest that individual and combined high expression of
TIM-3, LAG-3, and PD-1 on stromal immune cells are associated with better colorectal cancer prognosis,
suggesting there is added value to investigating multiple immune checkpoints simultaneously.
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Introduction
Colorectal cancer (CRC) contributes to about 10% of
reported cancer deaths worldwide [1]. Various factors
lead to CRC, including life-style choices, inherited
genetics such as Lynch syndrome (hereditary non-
polyposis colorectal cancer), and pre-existing chronic
conditions including inflammatory bowel disease
[2–5]. CRC staging is rapidly evolving from relying on
radiological and pathological assessment of the tumour
to recognising the importance of both molecular and
tumour microenvironment (TME) characteristics in
determining patient survival and treatment response
[6–11]. Additionally, emerging evidence supports the
use of markers of systemic inflammation prognostically
and predictively in advanced disease [12].
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For instance, increased immune response local to
the tumour has been shown to be provoked by
neoantigen-bearing mismatch repair (MMR) deficient
tumours, as evidenced by increased immune cell den-
sity [13–15]. However, characteristics of the TME are
not solely dependent on underlying tumour molecular
characteristics, and the prognostic value of the local
inflammatory response independent of MMR status is
increasingly recognised [16–18].
Indeed, immune-mediated inflammation, whether
systemic or local, is of prognostic value in CRC. How-
ever, whereas systemic inflammation, which is directly
related to poor prognosis is easily measured, TME
inflammation is more complicated [19], due to the
immune system’s dual role in cancer [20]. Hence,
understanding immune regulation within the TME is
imperative in understanding CRC prognosis.
Immune checkpoints are membrane proteins that regu-
late immune cells by either activating or inhibiting their
immune functions [21] and have the potential of acting
as prognostic biomarkers. Inhibitory checkpoints like
programmed cell death protein-1 (PD-1), T-cell immuno-
globulin mucin-domain containing-3 (TIM-3), and
lymphocyte-activation gene 3 (LAG-3), are all present on
T-cells and all bind to ligands that are secreted by tumour
cells [22]. PD-1, through its interaction with its ligand
PD-L1, aids tumours in evading anti-tumour immunity.
Hence, blocking this interaction is the aim of many thera-
peutic interventions [23]. However, intrinsic resistance
remains an issue. It has been reported that other inhibi-
tory immune checkpoints like TIM-3 and LAG-3 become
up-regulated during PD-1/PD-L1 blockage, to resist treat-
ment and allow cancer to progress [22,24]. Hence, com-
bined therapies targeting two or more of these inhibitory
checkpoints are being extensively investigated in various
stages of pre-clinical and clinical studies [25–27].
Since these immune checkpoints are of high therapeutic
value, investigating whether their assessment in the TME
holds prognostic significance is of great interest. There-
fore, the following study aimed to examine the prognostic
value of PD-1, PD-L1, TIM-3 and LAG-3 expression in
colorectal tumours and their microenvironment in samples
from patients who underwent curative resections of stage
I–III CRC. This expression was analysed in relation to
patient, tumour, and TME characteristics, systemic inflam-
mation, and cancer-specific survival.
Patients and methods
Patient characteristics and ethics statement
1009 stage I–III patients that had primary operable
CRC and underwent curative tumour resection surgery
in Glasgow Royal Infirmary, Western Infirmary, or
Stobhill Hospitals (Glasgow, UK) between 1997 and
2007 were included in the study. Patients who died
within 30 days of surgery or underwent neo-adjuvant
therapy were excluded. Previously constructed tumour
microarrays (TMAs) were utilised; four 0.6 mm cores
were available per patient to combat tumour heteroge-
neity. Tumour staging was carried out using the 5th
Edition of the AJCC/UICC-TNM staging system. All
patients were followed up for at least five years post
resection. This study was approved by the West of
Scotland Research Ethics Committee (16/WS/0207)
and patient information is held within the Glasgow
and Clyde Safe Haven (12/WS/0142).
Clinicopathological characteristics
Patient age, sex, adjuvant therapy status, tumour site,
staging, necrosis, venous invasion and resection margin
involvement were obtained from clinical records. Ki67
proliferation index was calculated as previously described
[28]. Tumour budding was assessed as previously
described within 10 high power fields [29]. MMR status
was previously determined for this cohort [16]. MMR
proteins MLH1, PMS2, MSH2 and MSH6 were assessed
by IHC, and scored deficient when there was loss of
staining of at least one MMR protein with normal expres-
sion within adjacent epithelium or intra-tumoural immune
cells.
TME characteristics
Tumour stroma percentage (TSP) was previously deter-
mined for this cohort [11]. Briefly, stromal percentage
was measured and was graded as low (≤50%) or high
(>50%). Inflammatory infiltrate was quantified using
the Klintrup–Mäkinen score as low-grade (no or mild
increase in inflammation), and high grade (prominent
increase in inflammation with cancer cell destruction)
as previously described [30]. The Glasgow Microenvi-
ronment Score (GMS) was constructed by combining
the TSP and the Klintup–Mäkinen as previously
described [31]. CD3+, CD8+ and FoxP3+ immune cell
density was assessed using an immunohistochemical
method, which included dewaxing and rehydration of
cores through graded alcohols, followed by antigen
retrieval in Tris–EDTA buffer at pH 8 under pressure,
then blocking of peroxidases and non-specific binding
using 3% H2O2 and 5% horse serum respectively.
Cores were incubated overnight at 4 C in anti-CD3 at
1:500 (ThermoFisher, Renfrew, UK), anti-CD8 at
1:100 (Dako, Copenhagen, Denmark), and anti-FoxP3
at 1:400 (Abcam, Cambridge, MA, USA). Following a
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30-min secondary antibody incubation (ImPRESS,
Vector Laboratories, Upper Heyford, UK), ImPACT
DAB (Vector Laboratories) was added as chromogen
and the slides were then counterstained with
haematoxylin, dehydrated and mounted with cover-
slips. Positive immune cells were counted withing the
cancer cell nest and stroma separately.
Systemic inflammation characteristics
Pre-operative C-reactive protein (CRP) and albumin
concentrations were recorded prospectively within
30 days of surgery. CRP >10 mg/l and albumin <35 g/l
were considered abnormal, and the modified Glasgow
Prognostic Score (mGPS) utilised these as previously
described [32]. The neutrophil-to-lymphocyte ratio
(NLR) was previously determined for this cohort
utilising a threshold of <3/3–5/>5 [33].
Immunohistochemistry and visualisation
TMAs were dewaxed in Histoclear (National Diagnos-
tics, CA, USA) followed by rehydration through a
decreasing gradient of ethanol. Heat-induced antigen
retrieval was carried out under pressure in a microwave
using Tris–EDTA Buffer at pH 9 for anti-TIM-3, and
citrate buffer at pH 6 for anti-PD-1, anti-LAG-3 and
anti-PD-L1. Endogenous peroxidase activity was
blocked in 3% H2O2. Non-specific antibody binding
was blocked using 10% casein (Vector Laboratories)
for anti-TIM-3 and anti-LAG-3 and 5% horse serum
(Vector Laboratories) for anti-PD-1 and anti-PD-L1.
TMAs were stained with anti-TIM-3 (Cat. TA355031,
OriGene, Rockville, MD, USA) at 1:1000 for 30 min at
RT, anti-PD1 (Product No.: HPA035981, Atlas Anti-
bodies, Bromma, Sweden) at 1:100, anti-PD-L1 (Cat.
17952-1-AP, Proteintech, Rosemont, IL, USA) at
1:100 and anti-LAG-3 (Cat.: HPA013967, Sigma-
Aldrich, Gillingham, UK) at 1:1,250, overnight at
4 C. TMAs were incubated for 30 min at RT in
ImmPress (TIM-3/LAG-3; Vector Laboratories) or
EnVision (PD-1 and PD-L1; Dako) and were visualised
with ImmPact 3,30-diaminobenzidine substrate (Vector
Laboratories). Samples were then counterstained in
Harris Haematoxylin (ThermoFisher) dehydrated in
increasing ethanol gradients and Histoclear, before
mounting with Omnimount (National Diagnostics).
TMAs were scanned using Hamamatsu NanoZoomer
Digital Slide Scanner and visualised in SlidePath (Ver-
sion 4.0.9, Leica Biosystems, Newcastle, UK). Nega-
tive control slides (no antibody, isotype-matched
antibody) were included to rule out nonspecific
staining. To ensure the positive staining was specific,
full section slides of colorectal cancer or liver tissue
were included as known positive controls, as well as
cell pellets (HT29) known to have positive expression
(see supplementary material, Figure S1).
Scoring methods
Scoring was performed by a single observer blinded to
the clinical data (SSFA for TIM-3, MVC for LAG-3
and LG for PD-1 and PD-L1). To ensure consistency,
10% of cores for each marker was co-scored by a sec-
ond observer (JE for TIM-3 and LAG-3 and JHP for
PD-1 and PD-L1). Tumour cell expression was
assessed using the weighted Histoscore method [34].
The weighted Histoscore was calculated as follows:
(% of unstained tumour cells × 0) + (% of weakly sta-
ined tumour cells × 1) + (% of moderately stained
tumour cells × 2) + (% of strongly stained tumour
cells × 3) to give a range from 0 to 300. All four cores
were scored separately, and an average score was
taken. Immune cells within the stroma expressing each
of the markers were assessed using a total point count
of positive lymphocytes for each core (Figure 1). Posi-
tive lymphocytes were recognised as brown membrane
and/or cytoplasmic stain with blue nuclei. Values from
four cores were averaged for each patient.
To ensure reliability and objectivity, 10% of cores
were scored digitally on QuPath [35]. In brief, after
using the TMA Dearrayer function to create a TMA
grid with cores in their correct positions, stain vectors
were estimated during pre-processing by the visual
stain editor available in QuPath, to increase staining
quality. Then, cells were detected using a watershed
cell detection method, and annotations were made to
allow QuPath to recognise a variety of tissue types.
These included tumour and stroma. Then, a random
trees classifier was trained using over 40 features such
as perimeter, area, and optical density. Three intensity
thresholds were used to represent negative, weak,
moderate and strong staining, and after the classifier
was built, the auto-update feature was used to re-
validate the classifier’s accuracy in real-time. The clas-
sifier was then saved and applied to all TMA slides
that were subjected to QuPath analysis.
Statistical analysis
Interclass correlation coefficient (ICCC) was used to
ensure consistency and objectivity between the main
scorer and the co-scorers and QuPath. Values above
0.75 are indicative of good reliability [36]. Immune
checkpoint expression in both the tumour and lympho-
cytes within the stroma was categorised as either ‘low’
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Figure 1. Immune checkpoint expression in colorectal cancer. TIM-3, LAG-3, PD-1 and PD-L1 showed cytoplasmic staining. For each
marker, the top right boxes show examples of positive lymphocytes in the stroma (red arrows); and the bottom right boxes show positive
tumour cells at a higher magnification with no-antibody negative controls within (insets). Scale bars at 100 μm.
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or ‘high’ utilising cut-offs determined using a receiver
operating characteristic (ROC) curve or median. ROC
curves were used for tumoural TIM-3 (132), LAG-3
(161), PD-1 (12) and PD-L1 (139) as well as TIM-3 (17),
PD-1 (1.6) and PD-L1 (4.6) expressed on stromal
immune cells, while the median was used for stromal
immune cells expressing LAG-3. Associations between
immune checkpoint expression and clinicopathological
characteristics were assessed using χ2-test. Immune
checkpoint expression and cancer-specific survival was
assessed using Kaplan–Meier survival curves with Log-
Rank testing. Univariate Cox regression survival analysis
was used to determine hazard ratios (HRs) and 95% con-
fidence intervals (CIs). Multivariable Cox regression sur-
vival analysis using a backward conditional elimination
model and a statistical significance threshold of 0.05 was
performed to identify independent prognostic biomarkers.
Due to the number of comparisons of clinicopathological
characteristics performed, a Bonferroni corrected P value
0.002 (0.05/22) was considered statistically significant
for χ2-tests. Otherwise, P values 0.05 were considered
significant. All statistical analysis was performed using
IBM SPSS Statistics Version 24 and was two-sided.
Results
Of the 1009 patients, 773 with stage I–III CRC were
eligible and had adequate tissue to be included in the
analysis (see supplementary material, Figure S2);
528 (68%) patients were over 65 years of age, with
395 (51%) being male. 107 (14%) patients were
TNM-I, 373 (48%) were TNM-II and 293 were
TNM-III (38%). Of this cohort, MMR data was valid
for 761 patients, 133 of which were MMR-deficient
(17%) and 628 of which were MMR-competent
(83%; see supplementary material, Table S4). The
median follow-up was 100 months with 222 cancer
deaths. 403 and 457 patients had valid scores for
tumour and stromal immune cells TIM-3 respectively,
413 and 387 had valid scores for tumour and stromal
immune cells LAG-3, 722 and 719 patients had valid
scores for tumour and stromal immune cells PD-1,
and 708 had valid scores for tumour and stromal
immune cells PD-L1 (see supplementary material,
Figure S2).
QuPath was used to score 10% of cores to ensure
reliability and objectivity of staining assessment. The
ICCC value of manual scores and QuPath scores was
0.827 for TIM-3, 0.756 for LAG-3, 0.842 for PD-1
and 0.795 for PD-L1.
Immune checkpoint expression is associated with
cancer-specific survival
Tumoural expression refers to tumour cell expression
and stromal immune cell expression refers to expres-
sion on immune cells within the stroma. Table 1 shows
the association between immune checkpoint expression
and cancer-specific survival. Tumoural TIM- 3 expres-
sion was not associated with survival (p = 0.188), and
neither was PD-L1 in the tumour (p = 0.487) or lym-
phocytes in the stroma (p = 0.298). However, high
tumoural LAG-3 (HR 1.45, 95% CI 1.00–2.09,
p = 0.049; Figure 2A) and PD-1 (HR 1.34, 95% CI
1.00–1.78, p = 0.047; Figure 2B) were significantly
associated with poor cancer-specific survival, whereas
high stromal immune cell expression of TIM-3
(HR 0.60, 95% CI 0.42–0.84, p = 0.003; Figure 2E),
LAG-3 (HR 0.58, 95% CI 0.40–0.87, p = 0.006; Figure
2C), and PD-1 (HR 0.65, 95% CI 0.49–0.86,
p = 0.002; Figure 2D) were significantly associated
with improved cancer-specific survival.
Table 1. Immune checkpoint expression in CRC patients and survival.
Tumour Stromal immune cells
n (%) 10 year CSS P value n (%) 10 year CSS P value
TIM-3 n = 401 n = 455
Low 206 68% 0.188 186 59% 0.003
High 195 74% 271 75%
LAG-3 n = 412 n = 386
Low 253 73% 0.049 196 63% 0.006
High 160 65% 191 78%
PD-1 n = 717 n = 714
Low 494 72% 0.047 308 65% 0.002
High 223 66% 406 75%
PD-L1 n = 704 n = 703
Low 452 71% 0.487 255 67% 0.298
High 252 68% 448 72%
Bold values are less than 0.05.
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Figure 2. Immune checkpoint expression in the tumour and stromal immune cells of colorectal cancer patients is significantly associated
with survival. Kaplan–Meier survival curves for associations between cancer-specific survival and (A) tumoural LAG-3, (B) tumoural
PD-1, (C) stromal immune cell LAG-3, (D) stromal immune cell PD-1 and (E) stromal immune cell TIM-3 expression.
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Immune checkpoint expression is associated with
patient characteristics and clinicopathological
parameters
Table 2 shows the relationship between prognostic
immune checkpoints, patient characteristics, tumour
characteristics, TME characteristics, and markers of sys-
temic inflammation. As there were more than 10 com-
parisons performed, all analysis was corrected using the
Bonferroni test. Therefore, associations were observed
between high TIM-3 expression on stromal immune
cells and high Klintrup–Mäkinen grade (p < 0.001) and
a low GMS (p < 0.001). Whereas, high tumoural PD-1
associated with younger patients (p < 0.001), rectal
tumours (p = 0.001), high TNM stage (p = 0.002), low
Ki67 index (p < 0.001), high budding (p = 0.002), and
unperforated tumours (p < 0.001). Finally, PD-1 stromal
immune cell expression associated with high Ki67
Index (p = 0.002), a high Klintrup–Mäkinen grade
(p < 0.001), and low GMS (p < 0.001). No significant
associations were seen for any other markers when
corrected using the Bonferroni test.
Immune checkpoint expression is associated with
the immune landscape
Next, associations with the local immune lymphocytic
infiltrate were assessed (see supplementary material,
Table S1). High TIM-3 stromal immune cell expression
was significantly associated with high stromal CD3+ T-
cells (p < 0.001) and a total CD3+ high in both cancer
cell nest and stroma score (p < 0.001), high CD8+ T-
cells in cancer cell nests (p = 0.001), high stromal
CD8+ T-cells (p < 0.001), a total CD8+ high in both
cancer cell nest and stroma score (p < 0.001), high stro-
mal FoxP3+ T-cells (p < 0.001) and a total FoxP3+ high
in both cancer cell nest and stroma score (p = 0.013).
In contrast, tumoural LAG-3 showed no significant
relation with T-cell markers. However, high LAG-3
stromal immune cell expression associated with high
CD3+ T-cells in cancer cell nests (p = 0.024), high stro-
mal CD3+ T-cells (p = 0.001), a total CD3+ high in
both cancer cell nest and stroma score (p = 0.002), high
CD8+ T-cells in cancer cell nest (p = 0.003), high stro-
mal CD8+ T-cells (p = 0.001) and a total CD8+ high in
both cancer cell nest and stroma score (p = 0.002).
High tumoural PD-1 was associated with low CD3+
T-cells in cancer cell nests (p < 0.001), a total CD3+
low in both cancer cell nest and stroma score
(p = 0.021), low CD8+ T-cells in cancer cell nests
(p = 0.001), low stromal CD8+ T-cells (p < 0.001),
and a total CD8+ low in both cancer cell nest and
stroma score (p < 0.001), as well as low FoxP3+ T-
cells in cancer cell nests (p < 0.001) and a total
FoxP3+ low in both cancer cell nest and stroma score
(p < 0.001). Finally, high PD-1 stromal immune cell
expression associated with high CD3+ T-cells in can-
cer cells nests (p < 0.001), high stromal CD3+ T-cells
(p < 0.001), a total CD3+ high in both cancer cell nest
and stroma score (p < 0.001), high CD8+ T-cells in can-
cer cell nests (p < 0.001), high stromal CD8+ T-cells
(p < 0.001), and a total CD8+ high in both cancer cell
nest and stroma score (p < 0.001), as well as high
FoxP3+ T-cells in cancer cell nests (p < 0.001), high stro-
mal FoxP3+ T-cells (p < 0.001) and a total FoxP3+ high
in both cancer cell nest and stroma score (p < 0.001).
Combined immune checkpoint stromal score
Since expression on immune cells in the stroma of all
three immune checkpoints displayed similar effects on
patient prognosis, they were combined into a single
score called the Combined Immune Checkpoint Stro-
mal Score (CICSS) to assess if this increased their
prognostic power. Only patients who had a valid score
for all three markers were considered (n = 309). CICSS
was defined as CICSS 3 = all 3 checkpoint markers
high, CICSS 2 = 2 checkpoint markers high, and
CICSS 1 = remaining patients. CICSS 3 significantly
associated with improved cancer-specific survival
(HR 0.57, 95% CI 0.42–0.78, p = 0.001; Figure 3). The
association between CICSS and clinicopathological
characteristics was investigated (see supplementary
material, Table S2). Again, as there were more than
10 comparisons, all analysis was corrected using the
Bonferonni test. CICSS 3 was significantly associated
with a high Klintrup–Mäkinen grade (p < 0.001) and a
low GMS (p = 0.001). Furthermore, when assessing
the local inflammatory infiltrate (see supplementary
material, Table S3), CICSS 3 was significantly associ-
ated with high CD3+ T-cells (p < 0.001) and CD8+ T-
cells (p < 0.001) in cancer cell nests, high stromal
CD3+ T-cells (p < 0.001) and CD8+ T-cells (p < 0.001)
and a total CD3+ or CD8+ high in both cancer cell nest
and stroma score (both p < 0.001), as well as high stro-
mal FoxP3+ T-cells (p = 0.001), and a total FoxP3+
high in both cancer cell nest and stroma score
(p = 0.010).
LAG-3 stromal immune cell expression is an
independent prognostic marker for CRC
Individual immune checkpoint markers and CICSS were
entered in univariate cox regression analysis as shown in
Table 3. TIM-3 (p = 0.003), LAG-3 (p = 0.007) and PD-
1 (p = 0.002) stromal immune cell expression, as well as
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tumoural PD-1 (p = 0.049) and CICSS (p < 0.001) were
significantly associated with cancer-specific survival.
These were taken forward into multivariate analysis with
other prognostic clinical factors (Table 3), where TNM
stage (p < 0.001), perforation (p = 0.001), GMS
(p < 0.001), mGPS (p = 0.001) and LAG-3 stromal
immune cell expression (p = 0.017) were independently
associated with cancer-specific survival.
Discussion
This retrospective study on the prognostic value of
the immune checkpoints TIM-3, LAG-3, PD-1 and
ligand PD-L1 highlights the importance of the
location and level of immune checkpoint expression
in terms of CRC prognosis. Of the immune check-
points investigated, high expression in the tumour
was associated with decreased cancer-specific sur-
vival, while on immune cells within the stroma it
was associated with improved cancer-specific sur-
vival. Furthermore, it supports the hypothesis that
there is increased value gained from investigating
multiple checkpoint markers as patients with stromal
immune cell expression of all three checkpoints had
the best prognosis.
To our knowledge, this is the first study to report
that LAG-3 and PD-1 are expressed in CRC tumour
cells. High PD-1 in the tumour was associated with
poorer survival and associated with poor prognostic
factors including low proliferation index [37]. This
Figure 3. Combined Immune Checkpoint Stromal Score is significantly associated with survival. Kaplan–Meier survival curves for associa-
tions between CICSS and cancer-specific survival.
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suggests a possible role of PD-1 in tumour progres-
sion. Furthermore, the positive association observed
between high tumoural PD-1 and low albumin [38]
suggests a link between tumoural PD-1 and systemic
inflammation. Moreover, high PD-1 in the tumour
associated with low CD3+, CD8+ and FoxP3+ T-cells,
which are also associated with poorer prognosis. How-
ever, since this is the first study to report the expres-
sion of LAG-3 and PD-1 in tumour cells, these results
require further validation. Since PD-1’s ligand PD-L1
was not associated with survival, this study focussed
on the immune checkpoint receptors’ prognostic value.
In contrast, it was observed that high immune
checkpoint expression on immune cells within the
stroma associated with improved cancer-specific sur-
vival and good prognostic factors. High PD-1 stromal
immune cell expression was shown to associate with
early TNM stage and high Ki67 index [37] and could
infer a role in regulation of growth and survival pro-
cesses. Moreover, high PD-1 stromal immune cell
expression was associated with both high Klintrup–
Mäkinen grade and low GMS, as well as high densi-
ties of markers of adaptive immunity (CD3, CD8 and
FoxP3). High Klintrup–Mäkinen grade and low GMS
have both been associated with improved survival,
with Klintrup–Mäkinen being associated with
increased levels of CD3, CD8 and FoxP3 and reduced
cancer recurrence, propagating a positive association
[31,39]. Hence, the results suggest that high PD-1 stro-
mal immune cell expression is a possible marker of
the host’s anti-tumour immune response.
As with PD-1 stromal immune cell expression, high
levels of TIM-3 and LAG-3 stromal immune cell
expression were individually associated with improved
outcomes and markers of different T-cell subsets.
CD3+ and CD8+ cells are associated with a favourable
Table 3. Immune checkpoint expression, clinicopathological characteristics and cancer-specific survival in CRC patients.
Univariate analysis Multivariate analysis
Individual checkpoints CICSS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (<65/>65 years) 1.03 (0.80–1.33) 0.815 – – – –
Sex (male/female) 1.13 (0.88–1.44) 0.333 – – – –
Tumour site (colon/rectum) 0.98 (0.84–1.14) 0.775 – – – –
T-stage (1/2/3/4) 1.94 (1.60–2.34) <0.001 0.96 (0.34–2.73) 0.938 0.98 (0.35–2.73) 0.974
N-stage (0/1/2) 2.06 (1.77–2.41) <0.001 1.07 (0.53–2.16) 0.862 1.15 (0.57–2.32) 0.691
TNM stage (I/II/III) 2.48 (2.01–3.06) <0.001 2.72 (1.59–4.66) <0.001 2.76 (1.63–4.67) <0.001
Ki67 index (low/high) 0.67 (0.53–0.86) 0.001 1.06 (0.49–2.28) 0.891 1.27 (0.67–2.43) 0.459
Tumour differentiation (well/poor) 2.02 (1.45–2.82) <0.001 1.10 (0.50–2.44) 0.812 1.11 (0.51–2.43) 0.796
Tumour budding (low/high) 1.30 (1.00–1.71) 0.060 – – – –
Tumour necrosis (low/high) 1.30 (1.01–1.66) 0.040 1.16 (0.63–2.12) 0.641 1.27 (0.71–2.27) 0.415
Tumour perforation (absent/present) 1.56 (1.27–1.92) <0.001 2.66 (1.61–4.40) <0.001 2.64 (1.56–4.36) <0.001
Margin involvement (absent/involved) 3.44 (2.35–5.04) <0.001 1.43 (0.62–3.28) 0.399 1.81 (0.84–3.90) 0.132
Venous invasion (absent/present) 2.14 (1.68–2.73) <0.001 1.72 (0.98–3.02) 0.059 1.63 (0.92–2.88) 0.093
Peritoneal involvement (uninvolved/involved) 2.56 (2.01–3.27) <0.001 1.03 (0.53–2.02) 0.921 0.92 (0.48–1.77) 0.795
MMR status (deficient/competent) 0.83 (0.59–1.16) 0.274 – – – –
TSP (low/high) 1.95 (1.50–2.52) <0.001 1.27 (0.22–7.175) 0.789 1.17 (0.21–6.60) 0.863
CD3 cancer cell nest (low/high) 0.56 (0.43–0.73) <0.001 0.82 (0.41–1.64) 0.572 1.02 (0.50–2.06) 0.960
CD3 stroma (low/high) 0.59 (0.45–0.76) <0.001 0.613 (0.35–1.08) 0.093 0.51 (0.29–0.88) 0.016
K-M score (low-grade/high-grade) 0.40 (0.29–0.55) <0.001 0.50 (0.16–1.59) 0.240 0.44 (0.14–1.38) 0.160
GMS (0/1/2) 1.89 (1.58–2.26) <0.001 2.20 (1.46–3.32) <0.001 2.00 (1.34–2.99) 0.001
CRP (normal/high) 2.09 (1.60–2.73) <0.001 0.60 (0.05–7.88) 0.699 0.32 (0.03–3.62) 0.358
Albumin (low/normal) 2.13 (1.61–2.82) <0.001 0.687 (0.28–1.71) 0.421 0.87 (0.37–2.04) 0.751
mGPS (0/1/2) 1.77 (1.50–2.08) <0.001 1.91 (1.31–2.77) 0.001 1.82 (1.25–2.67) 0.002
NLR (low/high) 1.43 (1.08–1.91) 0.013 0.74 (0.35–1.57) 0.436 0.86 (0.41–1.81) 0.691
Immune checkpoint expression
TIM-3 tumour (low/high) 0.78 (0.53–1.14) 0.190 – – – –
TIM-3 stromal immune cells (low/high) 0.60 (0.42–0.84) 0.003 0.75 (0.43–1.30) 0.306 – –
LAG-3 tumour (low/high) 1.45 (1.00–2.09) 0.051 – – – –
LAG-3 stromal immune cells (low/high) 0.58 (0.40–0.87) 0.007 0.50 (0.28–0.88) 0.017 – –
PD-1 tumour (low/high) 1.34 (1.00–1.78) 0.049 0.810 (0.42–1.55) 0.523 – –
PD-1 stromal immune cells (low/high) 0.65 (0.49–0.86) 0.002 1.48 (0.84–2.61) 0.172 – –
CICSS (1/2/3) 0.57 (0.42–0.78) <0.001 – – 0.856 (0.55–1.33) 0.486
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outcome [40] and FoxP3+ cells, although a marker of
the immunosuppressive regulatory T-cells (Tregs),
have also been reported to associate with better patient
survival in CRC [41]. This further supports the rela-
tion between expression of these immune checkpoints
in the stroma and improved patient survival due to
effects on the local lymphocytic infiltrate. However,
only LAG-3 stromal immune cell expression was an
independent prognostic factor, suggesting the other
two checkpoints may rely on LAG-3 for their function
or expression.
Since the effects of high expression of each immune
checkpoint on immune cells within the stroma had
similar effects on patient survival, they were combined
into a single score, CICSS, to investigate whether they
might work together to improve prognostic power. A
CICSS 3, where all three immune checkpoints are
highly expressed, significantly improved patient sur-
vival. This highlights the importance of investigating
the effects of immune checkpoints collectively rather
than individually as the prognostic power was
increased in the combined score compared to the
individual proteins. CICSS 3 also associated with
inflammatory factors of good prognosis such as high
Klintrup–Mäkinen grade, and low GMS, as well as
high levels of CD3+ T-cells, CD8+cytotoxic T-cells
and FoxP3+ Tregs. Taken together, these results sug-
gest that the combined high expression of these
immune checkpoints in the stroma is a marker of
the host’s anti-tumour immune response during the
early stages of cancer development. However,
CICSS was not an independent prognostic factor,
but this may be due to low patient numbers for this
analysis and needs validation in a larger independent
cohort, which would also serve to validate the
cut-offs.
These results are contrary to the current approach
towards these inhibitory checkpoints, which tends to
look at them as facilitators of tumour progression. Of
course, this approach is backed by functional studies
where blockage or inhibition of these checkpoints led
to tumour regression in many types of cancer such as
melanoma, non-small cell lung cancer, and even in
metastatic CRC [42–44]. However, it is important to
note the differences between the methodology used
here and in previous work. For instance, recent studies
have primarily focused on circulating immune cells,
tumour cells, cell lines, or animal models [45–49], and
few of them utilise CRC patient tissue or include all
three immune checkpoints [50–53].
To our knowledge, this paper is the first to investi-
gate these three immune checkpoints together in the
context of the human CRC TME and prognosis. These
findings could not only serve as a basis for including
multiple immune checkpoints in future prognostic
studies on CRC but could also be useful in clinical tri-
als. The adaptation of such prognostic information
may lead to the development of statistical models that
could predict the outcome of therapies in patients in
the same immune checkpoint expression subset. Fur-
ther functional analysis of these results is warranted,
and any underlying mechanisms must be elucidated.
The correlation between each of these checkpoints and
their tumour-secreted ligands would be interesting to
explore, as well as relating each immune checkpoint to
the T-cell subset it is most highly expressed in, and
whether there are any underlying associations with
common mutations such as BRAF.
In conclusion, these results suggest that high levels
of the inhibitory immune checkpoints TIM-3, LAG-3
and PD-1, whether individually or in combination, on
immune cells within the stroma are associated with
good prognosis and it was observed that stromal
LAG-3 is an independent prognostic factor. Finally,
the results point to the inclusion of all three immune
checkpoints in future investigation regarding CRC
prognosis.
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